Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683267 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement
A Phase 2 study, sponsored by Anesiva.
- Terminated
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT00683267 is a Phase 2 study that was terminated before completion, run by Anesiva. The registered enrollment target is 118 participants.
The verdict
NCT00683267, a Phase 2 study, was terminated before completion, sponsored by Anesiva.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
Evaluate the efficacy, safety and tolerability of a single intraoperative dose of 4975 in patients undergoing total hip replacement
Interventions
- DRUG Placebo
- DRUG 4975, highly purified capsaicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00683267
The ClinicalTrials.gov registry entry for NCT00683267 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anesiva, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00683267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00683267 about?
NCT00683267 is a clinical study titled "Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement". Evaluate the efficacy, safety and tolerability of a single intraoperative dose of 4975 in patients undergoing total hip replacement
What is the current status of trial NCT00683267?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2007-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00683267?
The interventions under investigation include: Placebo (DRUG), 4975, highly purified capsaicin (DRUG).
Who is sponsoring clinical trial NCT00683267?
This trial is sponsored by Anesiva, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.